Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug

Novartis has asked U.S. and European regulators to review its biosimilar of Biogen’s multiple sclerosis drug Tysabri, the company said Monday. If approved, the copycat version Tysabri could potentially launch as soon as next year.